Posted by Michael Wonder on 28 Jan 2021
Bio-Thera Solutions announces FDA accepts biologics license application for BAT1706, a proposed biosimilar to Avastin
28 January 2021 - Bio-Thera Solutions today announced that the U.S. FDA has accepted its biologics license application for BAT1706, a proposed biosimilar to Avastin (bevacizumab).
The FDA goal date set under the Biosimilar User Fee Act (BsUFA) is 27 November 2021.
